Eikon Therapeutics SEC filings: 8-K

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KOct. 26, 2026, 6 a.m. ETView on SEC.gov
Regulation FD disclosure · Other events · Financial statements and exhibits
AI summary, unreviewedEikon Therapeutics Reports 63.1% Objective Response Rate for EIK1001 in First-Line NSCLC at ESMO 2026, Squamous Cohort 72.4%
8-KOct. 23, 2026, 9:15 a.m. ETView on SEC.gov
Regulation FD disclosure · Other events · Financial statements and exhibits
AI summary, unreviewedEikon Therapeutics Presents Mixed Early Clinical Data for EIK1003, EIK1004 and EIK1005 at ESMO 2026, With Modest Response Rates
8-KAug. 13, 2026, 8:44 p.m. ETView on SEC.gov
Regulation FD disclosure · Financial statements and exhibits
8-KAug. 13, 2026, 4:06 p.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits
8-KAug. 3, 2026, 4:39 p.m. ETView on SEC.gov
Departure/appointment of directors or officers